Descriptive only
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); background therapy: one or more non insulin glucose lowering drugs
weeks 20 to 36 (target week 26)Not stated by the trialsDoses of a drug pooledMean differenceSeparate part 3 of a disconnected network
1
Randomized trials
2
Treatments
51
Participants
2
Trial arms
In plain language
No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 1 trial. The trial data below are shown as reported.
Network of trials
Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
Baseline characteristics of the trials
The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.
| Trial | Baseline BMI or body weight (kg/m2) effect modifier, prognostic factor; 1 of 1 | Sex (percent female) effect modifier, prognostic factor; 1 of 1 | Background glucose lowering therapy (stratum S0 to S4) effect modifier, prognostic factor; 1 of 1 | Asian ancestry or region (percent Asian) effect modifier, prognostic factor; 1 of 1 | Kidney function (eGFR) (mL/min/1.73 m2) prognostic factor, effect modifier; 1 of 1 | Treatment duration (weeks) effect modifier; 1 of 1 | Lifestyle co-intervention intensity (none standard intensive) effect modifier, prognostic factor; 1 of 1 |
|---|---|---|---|---|---|---|---|
| S003036 S003036 | 25.62 | 45.12 100 minus male share | S1 | 100 region: all sites in Asia | 71.98 | 24 | none |
Comparability of the trials
Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
No comparability concerns were found.
| Trial | time weeks | analysis set | definition | instrument | adjudicated | proportion method | intercurrent events (discontinuation) | intercurrent events (rescue) | blinding | funding | start year | Eligibility |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S003036 | 24 | completers | not stated | not stated | not stated | not stated | not stated | not stated | open_label | non_industry | 2022 | age 20 or more; HbA1c 7.0 percent or more; DPP-4 inhibitor for 12 weeks or more |
Trial data
What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the mean difference on the analysis scale against the trial's first row. Flags mark converted, combined or approximated inputs.
Rerun this analysis yourself
Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.